Jove
Visualize
Contact Us

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

12.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.6K
Conserved Binding Sites01:49

Conserved Binding Sites

4.1K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.1K
The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

56
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
56
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

X-ray Crystallography-Guided Discovery of a Potent Dual-Pocket Competitive SIRT5 Inhibitor against Sepsis-Associated AKI.

Journal of medicinal chemistry·2026
Same author

Correction to "Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence".

Journal of medicinal chemistry·2026
Same author

Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence.

Journal of medicinal chemistry·2026
Same author

Structural Optimization of Benzyl-5-methyl‑1<i>H</i>‑Imidazole Derivatives as Human Glutaminyl Cyclase Inhibitors.

ACS medicinal chemistry letters·2026
Same author

A Novel CSN5 Inhibitor Drives Tumor-Intrinsic PD-L1 Degradation and Exerts Direct Antitumor Efficacy in Triple-Negative Breast Cancer.

Journal of medicinal chemistry·2026
Same author

Evolution of Molecular Generation Models in Drug Discovery.

Journal of medicinal chemistry·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2025

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

1.2K

Knowledge-guided diffusion model for 3D ligand-pharmacophore mapping.

Jun-Lin Yu1, Cong Zhou1, Xiang-Li Ning1

  • 1Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.

Nature Communications
|March 6, 2025
PubMed
Summary
This summary is machine-generated.

DiffPhore, a novel AI framework, enhances drug discovery by accurately predicting 3D ligand-pharmacophore mappings. This method improves virtual screening and identifies novel drug candidates, advancing AI in pharmaceutical research.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

175
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Related Experiment Videos

Last Updated: May 24, 2025

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

1.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

175
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.3K

Area of Science:

  • Computational chemistry
  • Artificial intelligence in drug discovery
  • Pharmacophore modeling

Background:

  • Pharmacophores are crucial for drug discovery, but deep learning integration remains limited.
  • Existing tools often struggle with accurate 3D ligand-pharmacophore mapping.
  • Advancing AI-driven pharmacophore methods is essential for efficient drug development.

Purpose of the Study:

  • To introduce DiffPhore, a knowledge-guided diffusion framework for 'on-the-fly' 3D ligand-pharmacophore mapping.
  • To improve the accuracy and efficiency of predicting ligand binding conformations.
  • To enhance virtual screening capabilities for lead discovery and target fishing.

Main Methods:

  • Developed a knowledge-guided diffusion framework (DiffPhore) for ligand-pharmacophore mapping.
  • Utilized ligand-pharmacophore matching knowledge to guide ligand conformation generation.
  • Employed calibrated sampling to address exposure bias in iterative conformation searches.
  • Trained the model on two custom datasets of 3D ligand-pharmacophore pairs.

Main Results:

  • DiffPhore achieved state-of-the-art performance in predicting ligand binding conformations.
  • Outperformed traditional pharmacophore tools and advanced docking methods.
  • Demonstrated superior virtual screening power for lead discovery and target fishing.
  • Successfully identified novel inhibitors for human glutaminyl cyclases with validated binding modes.

Conclusions:

  • DiffPhore represents a significant advancement in AI-enabled pharmacophore-guided drug discovery.
  • The framework offers improved accuracy and efficiency for identifying potential drug candidates.
  • This work paves the way for broader adoption of deep learning in pharmacophore-based drug design.